TLPPF
Telix Pharmaceuticals Ltd
$9.41
+2.28%
No data for this timeframe.
Vol
SEC Reports10
Recent Activity
May 21, 2026
SEC
Telix Pharmaceuticals filed its Annual General Meeting (AGM) materials on May 21, 2026, including Chairman/CEO addresses
6-K — Impact 2/10
May 18, 2026
SEC
David N. Gill filed a Form 3 initial statement of beneficial ownership with the SEC, reporting no securities beneficiall
3 — Impact 2/10
May 18, 2026
SEC
William Jellison filed a Form 3 initial statement of beneficial ownership with Telix Pharmaceuticals Ltd, reporting no s
3 — Impact 2/10
Analyst Ratings
5Strong Buy
12Buy
1Hold
0Sell
0Strong Sell
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
10 SEC filing reports analyzed. Sentiment: 4 bullish, 0 bearish, 0 mixed, 6 neutral. Avg impact: 4.1/10.
NEUTRAL
6-K
2/10
Telix Pharmaceuticals filed its Annual General Meeting (AGM) materials on May 21, 2026, including Ch
May 21, 2026
NEUTRAL
3
2/10
David N. Gill filed a Form 3 initial statement of beneficial ownership with the SEC, reporting no se
May 18, 2026
NEUTRAL
3
2/10
William Jellison filed a Form 3 initial statement of beneficial ownership with Telix Pharmaceuticals
May 18, 2026
NEUTRAL
3
2/10
Maria Rivas filed a Form 3 initial statement of beneficial ownership with the SEC, reporting no secu
May 18, 2026
NEUTRAL
6-K
2/10
Telix Pharmaceuticals announced its upcoming annual general meeting (AGM), proxy form, and online gu
Apr 21, 2026
BULLISH
6-K
7/10
Telix Pharmaceuticals successfully priced and upsized its convertible bond offering to $600 million,
Apr 14, 2026
BULLISH
6-K
7/10
Telix Pharmaceuticals and Regeneron announced a radiopharma collaboration, which is a significant st
Apr 13, 2026
BULLISH
6-K
7/10
Telix Pharmaceuticals announced that the FDA has accepted the resubmitted New Drug Application (NDA)
Apr 10, 2026
NEUTRAL
6-K
2/10
Telix Pharmaceuticals announced the appointment of two new non-executive directors, Maria Rivas and
Apr 9, 2026
BULLISH
6-K
8/10
Telix Pharmaceuticals reported strong Q1 2026 revenue growth of 11% quarter-over-quarter to $230 mil
Apr 7, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 94% buy across 18 analysts — 5 strong buy, 12 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.3B | — | — |
| Next Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.3B | — | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $1.4B | 13.4% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $1.6B | 17.1% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 12 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 5 | 11 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 5 | 11 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 5 | 11 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 5 | 11 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 5 | 10 | 2 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.